Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Recommendation of “Hold” from Brokerages

Heron Therapeutics, Inc. (NASDAQ:HRTX) has received a consensus rating of “Hold” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $4.50.

HRTX has been the subject of a number of recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Heron Therapeutics in a research note on Friday, January 9th.

Institutional Investors Weigh In On Heron Therapeutics

Large investors have recently modified their holdings of the stock. State of Wyoming bought a new position in shares of Heron Therapeutics during the fourth quarter valued at approximately $76,000. Monaco Asset Management SAM boosted its position in shares of Heron Therapeutics by 23.0% in the 4th quarter. Monaco Asset Management SAM now owns 1,233,022 shares of the biotechnology company’s stock worth $1,603,000 after purchasing an additional 230,546 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Heron Therapeutics by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 4,081,222 shares of the biotechnology company’s stock worth $5,306,000 after buying an additional 438,240 shares during the last quarter. JW Asset Management LLC grew its stake in shares of Heron Therapeutics by 11.5% in the 4th quarter. JW Asset Management LLC now owns 3,671,073 shares of the biotechnology company’s stock worth $4,772,000 after buying an additional 378,440 shares during the last quarter. Finally, Tejara Capital Ltd increased its position in Heron Therapeutics by 11.8% during the 4th quarter. Tejara Capital Ltd now owns 5,131,426 shares of the biotechnology company’s stock valued at $6,671,000 after buying an additional 541,711 shares in the last quarter. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Trading Down 7.9%

NASDAQ:HRTX opened at $1.17 on Thursday. The firm has a market capitalization of $214.53 million, a P/E ratio of -13.00 and a beta of 1.25. The company has a quick ratio of 1.78, a current ratio of 2.56 and a debt-to-equity ratio of 19.89. The company has a fifty day moving average of $1.34 and a 200 day moving average of $1.31. Heron Therapeutics has a 52 week low of $1.00 and a 52 week high of $2.68.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.